Devyser Diagnostics AB
STO:DVYSR
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
66.4
139
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DVYSR stock under the Base Case scenario is 124.25 SEK. Compared to the current market price of 131.5 SEK, Devyser Diagnostics AB is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Devyser Diagnostics AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DVYSR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Devyser Diagnostics AB
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Devyser Diagnostics AB
Balance Sheet Decomposition
Devyser Diagnostics AB
Current Assets | 258.9m |
Cash & Short-Term Investments | 171.4m |
Receivables | 49.5m |
Other Current Assets | 38m |
Non-Current Assets | 204m |
PP&E | 100m |
Intangibles | 82.9m |
Other Non-Current Assets | 21.1m |
Current Liabilities | 61.5m |
Accounts Payable | 10.1m |
Accrued Liabilities | 26.2m |
Other Current Liabilities | 25.2m |
Non-Current Liabilities | 52.4m |
Long-Term Debt | 47.5m |
Other Non-Current Liabilities | 4.9m |
Earnings Waterfall
Devyser Diagnostics AB
Revenue
|
198m
SEK
|
Cost of Revenue
|
-39.6m
SEK
|
Gross Profit
|
158.4m
SEK
|
Operating Expenses
|
-235.9m
SEK
|
Operating Income
|
-77.5m
SEK
|
Other Expenses
|
6.1m
SEK
|
Net Income
|
-71.4m
SEK
|
Free Cash Flow Analysis
Devyser Diagnostics AB
SEK | |
Free Cash Flow | SEK |
DVYSR Profitability Score
Profitability Due Diligence
Devyser Diagnostics AB's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Devyser Diagnostics AB's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
DVYSR Solvency Score
Solvency Due Diligence
Devyser Diagnostics AB's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Devyser Diagnostics AB's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DVYSR Price Targets Summary
Devyser Diagnostics AB
According to Wall Street analysts, the average 1-year price target for DVYSR is 146.63 SEK with a low forecast of 101 SEK and a high forecast of 201.6 SEK.
Dividends
Current shareholder yield for DVYSR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DVYSR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one DVYSR stock under the Base Case scenario is 124.25 SEK.
Compared to the current market price of 131.5 SEK, Devyser Diagnostics AB is Overvalued by 6%.